CS 20BR08
Alternative Names: CS-20BR08; HLA-haplo Matched Allogenic Bone Marrow Derived Stem CellsLatest Information Update: 31 Jul 2023
At a glance
- Originator CORESTEM
- Developer Corestemchemon
- Class Mesenchymal stem cell therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Ataxia
Most Recent Events
- 28 Nov 2022 No recent reports of development identified for clinical-Phase-Unknown development in Ataxia in South Korea (Intrathecal, Injection)